International Journal of Hematology

, Volume 89, Issue 5, pp 664–672 | Cite as

Clinical profile of dasatinib in Asian and non-Asian patients with chronic myeloid leukemia

  • Dong-Wook Kim
  • Yeow-Tee Goh
  • Hui-Hua Hsiao
  • Priscilla B. Caguioa
  • Dongho Kim
  • Wan-Seok Kim
  • Tapan Saikia
  • Shruti Agrawal
  • Amit Roy
  • David Dai
  • M. Brigid Bradley-Garelik
  • Jaydip Mukhopadhyay
  • Saengsuree Jootar
Original Article


Resistance and intolerance to imatinib are of particular clinical relevance to Asian patients because of their lower body surface area. Dasatinib is 325-fold more potent than imatinib in inhibiting BCR-ABL in vitro and is indicated for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib. Data from a series of phase I/II research trials were analyzed to compare the efficacy, safety and pharmacokinetic profile of dasatinib 70 mg twice daily in Asian and non-Asian patients. Results from 55 Asian and 615 non-Asian patients demonstrated that the efficacy and safety of dasatinib was comparable. Dasatinib was well tolerated, with no observed toxicities exclusive to Asian patients. A higher incidence of adverse events and lower rate of response observed among Asian patients with myeloid blast phase CML reflected the aggressive nature of the disease. Analyses of noncompartmental pharmacokinetics (5 Asian and 49 non-Asian patients) and population pharmacokinetics (17 Asian and 382 non-Asian patients) were also comparable. The efficacy, safety and pharmacokinetic profile of dasatinib 70 mg twice daily is similar in Asian and non-Asian patients with CML. Dasatinib is therefore an important therapeutic option for this patient population.


Dasatinib Chronic myeloid leukemia Asian Pharmacokinetics Cytogenetic response 



In addition to the authors, the following primary investigators also provided patient data for this analysis: France, Francois-Xavier Mahon; Sweden, Bengt Simonsson; USA, Jorge Cortes, H. Jean Khoury and Michael Mauro. Funding for this research was provided by Bristol-Myers Squibb. Editorial and writing support was provided by Gardiner-Caldwell US, funded by Bristol-Myers Squibb.


  1. 1.
    Ries LAG, Melbert D, Krapcho M, et al, editors. SEER Cancer Statistics Review, 1975–2005, National Cancer Institute. Bethesda,, based on November 2007 SEER data submission, posted to the SEER web site, 2008.
  2. 2.
    Wing YA, Priscilla BC, Chuah C, et al. Chronic myeloid leukemia in Asia. Int. J Hematol. 2009;89:14–23. doi: 10.1007/s12185-008-0230-0.Google Scholar
  3. 3.
    Kantarjian H, Talpaz M, O’Brien S, et al. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood. 2003;101:473–5. doi: 10.1182/blood-2002-05-1451.PubMedCrossRefGoogle Scholar
  4. 4.
    Druker BJ, Guilhot F, O’Brian S, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408–17. doi: 10.1056/NEJMoa062867.PubMedCrossRefGoogle Scholar
  5. 5.
    Park SJ, Choi IK, Seo HY, et al. Reduced dose of imatinib for patients with chronic myeloid leukemia and low body surface area. Acta Haematol. 2007;118:219–21. doi: 10.1159/000111777.PubMedCrossRefGoogle Scholar
  6. 6.
    Horikoshi A, Takei K, Sawada S. Effects of lower dose of imatinib to CML patients. Leukemia Res. 2003;27:1167. doi: 10.1016/S0145-2126(03)00101-2.CrossRefGoogle Scholar
  7. 7.
    Horikoshi A, Takei K, Sawada S. Relationship between daily dose of imatinib per square meter and its plasma concentration in patients with chronic phase chronic myeloid leukemia (CML). Leukemia Res. 2007;31:569–75. doi: 10.1016/j.leukres.2006.05.019.CrossRefGoogle Scholar
  8. 8.
    Picard S, Titier K, Etienne G, et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood. 2007;109:3496–9. doi: 10.1182/blood-2006-07-036012.PubMedCrossRefGoogle Scholar
  9. 9.
    Larson RA, Druker BJ, Guilhot F, et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood. 2008;111:4022–8. doi: 10.1182/blood-2007-10-116475.PubMedCrossRefGoogle Scholar
  10. 10.
    Tokarski JS, Newitt JA, Chang CY, et al. The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res. 2006;66:5790–7. doi: 10.1158/0008-5472.CAN-05-4187.PubMedCrossRefGoogle Scholar
  11. 11.
    O’Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005;65:4500–5. doi: 10.1158/0008-5472.CAN-05-0259.PubMedCrossRefGoogle Scholar
  12. 12.
    Lombardo LJ, Lee FY, Chen P, et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem. 2004;47:6658–61. doi: 10.1021/jm049486a.PubMedCrossRefGoogle Scholar
  13. 13.
    Nam S, Kim D, Cheng JQ, et al. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res. 2005;65:9185–9. doi: 10.1158/0008-5472.CAN-05-1731.PubMedCrossRefGoogle Scholar
  14. 14.
    Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354:2531–41. doi: 10.1056/NEJMoa055229.PubMedCrossRefGoogle Scholar
  15. 15.
    Hochhaus A, Kantarjian HM, Baccarani M, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood. 2007;109:2303–9. doi: 10.1182/blood-2006-09-047266.PubMedCrossRefGoogle Scholar
  16. 16.
    Guilhot F, Apperley J, Kim DW, et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood. 2007;109:4143–50. doi: 10.1182/blood-2006-09-046839.PubMedCrossRefGoogle Scholar
  17. 17.
    Cortes J, Rousselot P, Kim DW, et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood. 2007;109:3207–13. doi: 10.1182/blood-2006-09-046888.PubMedCrossRefGoogle Scholar
  18. 18.
    Kantarjian H, Pasquini R, Hamerschlak N, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood. 2007;109:5143–50. doi: 10.1182/blood-2006-11-056028.PubMedCrossRefGoogle Scholar
  19. 19.
    Ottmann O, Dombret H, Martinelli G, et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a Phase II study. Blood. 2007;110:2309–15. doi: 10.1182/blood-2007-02-073528.PubMedCrossRefGoogle Scholar
  20. 20.
    Dai G, Pfister M, Blackwood-Chirchir A, Roy A. Importance of characterizing determinants of variability in exposure: application to dasatinib in subjects with chronic myeloid leukemia. J Clin Pharmacol. 2008 (Epub ahead of print).Google Scholar
  21. 21.
    SPRYCEL® (dasatinib) [package insert]. Princeton: Bristol-Myers Squibb Company; 2008.Google Scholar
  22. 22.
    Quintás-Cardama A, Kantarjian H, O’Brien S, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol. 2007;25:3908–14. doi: 10.1200/JCO.2007.12.0329.PubMedCrossRefGoogle Scholar
  23. 23.
    Shah NP, Kantarjian HM, Kim DW, et al. Intermittent target inhibition with dasatinib (100 mg once daily) preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol. 2008;26:3204–12. doi: 10.1200/JCO.2007.14.9260.PubMedCrossRefGoogle Scholar
  24. 24.
    Wang X, Hochhaus A, Kantarjian HM, et al. Dasatinib pharmacokinetics and exposure-response: relationship to safety and efficacy in patients with chronic myeloid leukemia. J Clin Oncol. 2008;26S:175s. abstract 3590.Google Scholar
  25. 25.
    Kantarjian HM, Shan J, Smith T, et al. Response to therapy is independently associated with survival prolongation in chronic myelogenous leukemia in the blastic phase. Cancer. 2001;92:2501–7. doi: 10.1002/1097-0142(20011115)92:10<2501::AID-CNCR1600>3.0.CO;2-N.PubMedCrossRefGoogle Scholar
  26. 26.
    Giles FJ, Cortes JE, Kantarjian HM, O’Brien SM. Accelerated and blastic phases of chronic myelogenous leukemia. Hematol Oncol Clin North Am. 2004;18:753–74. doi: 10.1016/j.hoc.2004.03.005.PubMedCrossRefGoogle Scholar
  27. 27.
    Sakamaki H, Ishizawa K, Taniwaki M, et al. Dasatinib phase I/II study of patients with chronic myeloid leukemia (CML) resistant or intolerant to imatinib: Results of the CA180031 study in Japan. J Clin Oncol. 2007;25(18S):681s. abstract 17515.Google Scholar
  28. 28.
    Wang L, Christopher LJ, Cui D, et al. Identification of the human enzymes involved in the oxidative metabolism of dasatinib. An effective approach for determining metabolite formation kinetics. Drug Metab Dispos. 2008 (epub ahead of print).Google Scholar
  29. 29.
    Eley T, Varga A, Sanil J, et al. The effects of rifampin on the pharmacokinetics of dasatinib and two metabolites in healthy subjects. American Association of Pharmaceutical Scientists (AAPS) Annual Meeting 2006. Abstract 003076.Google Scholar
  30. 30.
    Lal S, Wong ZW, Sandanaraj E, et al. Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients. Cancer Sci. 2008;99:816–23. doi: 10.1111/j.1349-7006.2008.00744.x.PubMedCrossRefGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2009

Authors and Affiliations

  • Dong-Wook Kim
    • 1
  • Yeow-Tee Goh
    • 2
  • Hui-Hua Hsiao
    • 3
  • Priscilla B. Caguioa
    • 4
  • Dongho Kim
    • 1
  • Wan-Seok Kim
    • 1
  • Tapan Saikia
    • 5
    • 6
  • Shruti Agrawal
    • 7
  • Amit Roy
    • 7
  • David Dai
    • 7
  • M. Brigid Bradley-Garelik
    • 7
  • Jaydip Mukhopadhyay
    • 7
  • Saengsuree Jootar
    • 8
  1. 1.Division of Hematology, Seoul St. Mary’s HospitalThe Catholic University of KoreaSeoulKorea
  2. 2.Department of HematologySingapore General HospitalSingaporeSingapore
  3. 3.Division of Hematology, Kaohsiung Medical University HospitalKaohsiung Medical UniversityKaohsiungTaiwan
  4. 4.Faculty of Medicine and Surgery, St. Luke’s Medical CenterUniversity of St. TomasManilaPhilippines
  5. 5.Department of MedicinePrince Aly Khan HospitalMumbaiIndia
  6. 6.Department of MedicineJaslok HospitalMumbaiIndia
  7. 7.Bristol-Myers SquibbLawrencevilleUSA
  8. 8.Department of Medicine, Faculty of MedicineRamathibodi HospitalBangkokThailand

Personalised recommendations